June 24, 2020

  • Updated June 29

The Texas Drug Utilization Review Board will perform a clinical review at their Oct. 23, 2020, meeting of anticonvulsants, antihemophilic, antineoplastic (i.e., anti-cancer), antiretroviral (i.e., anti-HIV), and medications used to treat multiple sclerosis. These are protected drug classes not currently reviewed on the Texas Medicaid Preferred Drug List (PDL). All medications within these newly-reviewed drug classes will be preferred and continue to be available without prior authorization.

Medications within these new drug classes do not currently undergo clinical review for efficacy, clinical significance, or safety. Including these new drug classes on the PDL will allow the DUR Board to perform a clinical review of all medications in the following categories:

  • Anticonvulsants
  • Antihemophilic
  • Antineoplastic (anti-cancer)
  • Antiretroviral (anti-HIV)
  • Medications used to treat multiple sclerosis

All medications within these newly-reviewed drug classes will have a preferred status on the PDL after board review and will continue to be available without prior authorization. The July 24, 2020, board meeting will include an announcement regarding the new drug classes planned for review at the Oct. 23 meeting.

In accordance with the usual solicitation process, Magellan will provide a supplemental rebate solicitation regarding these new drug classes.

Tags: 
Clinical PA
DUR Board
PDL